BioStock: Ultimovacs Begins Clinical Evaluation of Novel TET-Platform

After presenting their 2020 Q4 report, Ultimovacs immediately turned their attention back to 2021 by announcing the initiation of a new phase I study, TENDU. The TENDU trial is aimed at testing the company’s TET-platform in prostate cancer patients. The platform is based on innovative patented technology that has the potential to generate multiple cancer vaccine candidates.

Read the full article at biostock.se:

https://www.biostock.se/2021/02/ultimovacs-paborjar-klinisk-evaluering-av-ny-tet-platform/

This is a press release from BioStock - Connecting Innovation & Capital.